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Summary
AHCY deficiency is a new human methylation disorder, discovered recently in Cro-
atia, and a natural model for investigating processes related to the methylome. Methyla-
tion plays an important role in regulating biological processes and is crucial for gene 
expression, imprinting, signalling, protein synthesis and lipid metabolism. Thus, methy-
lation has broad impact and provides a suitable base for interdisciplinary research. Link-
ing genomics, proteomics, cellomics, lipidomics and metabolomics and other omics 
approaches may create a new research avenue – ‘AHCYdomics’ - a new methylation 
research platform based on AHCY deficiency. Using such research platform will allow 
to efficiently explore the full potential of the human methylation disorder AHCY defi-
ciency, and to design methods and approaches that will lead to a better understanding 
of the human methylome. 
Keywords: Methylomics; omics research; methyltransferase; transmethylation; ho-
mocysteine; genotype – phenotype
Abbreviations
AHCY: S-adenosylhomocystein hydrolase; SAM: S-adenosylmethionine; 
snRNA: small nuclear RNA; SAH: S-adenosylhomocysteine; MT: methyltrans-
ferase; MS: methinone synthase; BHMT: betaine-homocysteine methyltrans-
ferase; MAT: methionine-adenosyltransferase; ATP: adenosine-triphosphate; 
RBCs: red blood cells; PEMT: phosphatidylethanolamine-methyltransferase; 
PIMT: protein-isoaspartyl-methyltransferase; PTC: phosphatidylcholine;
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Introduction
At the molecular level, cellular functions form an extremely complex net-
work of  interdependent biochemical reactions. Fundamental processes such as 
cell division, death and differentiation depend on the precise regulation of gene 
expression, mRNA transcript stability and/or on the posttranslational modifica-
tions of effector proteins’ functionality. 
Methylation of various cellular substrates is directly linked to a variety of 
biochemical pathways. DNA 5’-cytosine methylation is widely known mecha-
nism of gene regulation, being one of the most important epigenetic mecha-
nisms [1-3] Coordinated methylation of specific arginines and lysines within 
unstructured N-terminal histone tails creates the ‘histone methylation pattern’, 
which is yet another level of fine tuning of gene expression, chromatin stabil-
ity and epigenetic memory [4-6]. Apart from those epigenetic roles, cellular 
methylations are also an integral part of different metabolic pathways, includ-
ing synthesis of monoamine neurotransmitters, detoxification reactions, mRNA, 
tRNA and snRNA processing [7,8], creatine and membrane phosphatidylcholine 
synthesis and the repair of proteins damaged by isomerization of aspartyl resi-
dues [9]. Lipid methylation might play a role in maintaining membrane fluidity, 
although still under debate [10,11]; in addition, methylations of specific signal 
proteins are neccesary for the smooth flow of information within complex sig-
nalling cascades [12].
Cellular methylations are catalyzed by substrate-specific methyltransferase 
enzymes. So far, over 60 distinct mammalian methyltransferases have been de-
scribed [13], with substrates ranging in size from arsenite to DNA, RNA and 
proteins. MTs can be classified into 5 different structural families, and some 
major MT’s are shown in table 1; although many of them share similar structural 
features, more recent studies have proven the existence of extensive functional 
convergence that is catalyzed by enzymes with remarkably distinct structures 
[14]. 
However, all those enzymes share the same methyl donor: S-adenosylme-
thionine (SAM). After ATP, SAM is the second most abundant enzyme substrate 
in nature, and the preference for SAM over other methyl donors such as folate 
can be explained thermodynamically [14,15]. Apart from methylated substrate, 
SAM-dependent methylation reactions result in formation of S-adenosylhomo-
cysteine (SAH). SAH is hydrolyzed to adenosine and homocysteine by S-ade-
nosylhomocysteine hydrolase (AHCY). While adenosine is further deaminated 
to inosine by adenosine-deaminase (ADA), homocysteine is either remethylated 
to methionine or enters the transsulfuration pathway resulting in formation of 
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cystathionine or, finally, cysteine. Remethylation pathway enzymes methinone 
synthase (MS) and betaine-homocysteine methyltransferase (BHMT) together 
with methionine-adenosyltransferases (MATs) and AHCY complete the meta-
bolic cycling of methionine and homocysteine (see figure 1). 
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It is known that SAH strongly inhibits many SAM-dependent methyltrans-
ferases [16]. Therefore, it is clear that tight regulation of SAH levels (or the SAM/
SAH ratio) is crucial for maintaining the proper methylation potential in the 
cell. In view of the fact that SAH hydrolysis is the only source of homocysteine 
in mammals, it is obvious that impaired AHCY activity would affect a wide va-
riety of cellular processes. Knock-out studies in mice have generally confirmed 
this by demonstrating early embryo lethality in animals harboring deletions in 
AHCY gene [17]. Elevated homocysteine levels have been reported as a risk fac-
tor for dementia and Alzheimer’s disease [18] and present a possible risk marker 
for vascular disease [19, 20]. 
Three-dimensional structure of human AHCY is solved by X-ray diffraction, 
and catalytic mechanism has been proposed [21,22]. Reaction steps involve  ini-
tial oxidation of SAH by the cofactor NAD+ to the 3-keto derivative, β-elimination 
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of homocysteine, Michel addition of water and the final reduction step which re-
leases adenosine [23,24]. The reaction is reversible, favoring SAM synthesis, and 
in this way hydrolytic reaction is dependent on rapid removal of both products. 
In human, AHCY is a homotetrameric enzyme with a tightly bound single NAD 
cofactor molecule per subunit [23]. 
Figure 1. MS, methionine synthase; BHMT, betaine-homocysteine methyltransferase; MAT, 
methionine adenosyltransferase
Known inherited metabolic disorders of the methionine-homocysteine path-
way include MAT deficiency [25,26], GNMT deficiency [27], and the most recent-
ly described AHCY deficiency. All three disorders share some common features. 
In this review, however, we will discuss this novel metabolic disease and some 
of the advances in understanding its molecular background, structural and cata-
lytic features of mutant AHCY as well as the potential of using the disease as 
model system for future methylation research. 
S-adenosylhomocysteine hydrolase deficiency - Diagnostics and clinical presen-
tation/manifestation
Deficiency of AHCY was firstly described in an croatian infant who exhibit-
ed delayed psychomotor development, myopathy and hypotonia, sluggishness, 
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lack of interest, poor head control and absent tendon reflexes. Physical therapy 
did not yield in significant improvement of described conditions [28]. Further, 
until the age of 12.8 months, when the diagnosis was confirmed, the patient’s 
psychomotor development showed very little progress. Also, cognitive func-
tions could not be evaluated due to his brief attention span. Brain MRI showed 
signs of white-matter atrophy and delayed myelination. Mild chronic hepatitis 
was detected, and many hepatocytes seemed to lack any rough endoplasmatic 
reticulum (ER), while smooth ER was hyperplastic. Numerous myelin figures 
were detected in muscle by electron microscopy, and the authors described the 
muscle histology as indicative of slowly progressive, destructive myopathy. Bio-
chemical abnormalities included elevation of plasma alanine aminotransferase, 
aspartate aminotransferase and creatine kinase, prolonged prothrombin time 
and low fibrinogen. However, it was the levels of sulphur-containing metab-
olites that set the direction of the diagnostic process. Specifically, the patient 
showed increased levels of methionine (477-784μM; reference values ranging 
from 13 to 45μM); SAM was approx. 30x above normal, and SAH was increased 
over 150x compared to reference values. At the same time, Hcy was only slightly 
above normal. Such pattern of metabolic deviations has never been described 
before, and the authors concisely and elegantly ruled out all known disorders 
that could lead to similar abnormalities, and pinpointed AHCY as the key en-
zyme in pathogenesis of the disease. Indeed, AHCY activity was significantly 
decreased as measured in liver extracts and RBC lysates. Sequence analysis of 
the AHCY gene revealed two mutations: a maternally derived nonsense mu-
tation that introduces a stop codon at amino acid 112 (W112stop) and a pater-
nally derived mutation replacing tyrosine 143 with cysteine (Y143C). The same 
genotype was also found in two younger brothers of the index patient who also 
showed very similar symptoms [29, 30]. Information about long-term clinical 
outcome of AHCY deficiency came from another patient, being the only proven 
case of the disease in an adult [31]. Only until recently this patient (also showing 
severe myopathy and developmental delay, accompanied by obsessive behavior 
and attention deficit disorder) was diagnosed simply with ‘isolated persistent 
hypermethioninemia’. In the light of the discovery of the first AHCY deficiency 
case, this patient was also tested for SAM, SAH, Hcy and methionine levels, 
which confirmed AHCY deficiency. Strikingly, although there is no connection 
to Croatian patients, the same Y143C mutation was found, in addition to alanine 
to valine exchange at position 89 [32].
The most severe form of AHCY deficiency is presented by an infant patient 
who died from respiratory insufficiency and liver failure at the age of only 4 
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months [33]. Metabolic and clinical record raised the possibility that deficiency 
of AHCY could be the underlying cause of the lethal outcome. By sequencing us-
ing the archive material, two point mutations were found, arginine to cysteine 
exchange at position 49 (R49C) and the substitution of aspartate for glycine at 
position 86 (D86G) [33].
Genetic background of AHCY deficiency
In humans, AHCY gene is located on the longer arm of chromosome 20 
(20q13) and consists of 10 exons. Resulting protein molecule is a homotetramer of 
432aa (amino acid) subunits, with one NAD molecule bound tightly per subunit. 
So far, 5 polymorphic AHCY isoforms were detected in population by starch gel 
electrophoresis, with some of them characterized at the molecular level [34-37]. 
None of those polymorphysms seem to have significant effects on the activity of 
AHCY. Nevertheless, mutations found in patients described above have a great 
impact on enzymatic capabilities of the enzyme, and are clustered in exons 2, 3 
and 4 (figure 2). None of those mutations were found by sequencing AHCY genes 
from more than 130 control individuals from Croatian population [28], which in-
dicates that Y143C, A89V, D86G or R49C are not common polymorphisms. Both 
parents of Croatian patients are heterozygous for W112stop and Y143C (mother 
and father, respectively) and do not show any metabolic abnormalities, although 
the father’s psychomotor development was somewhat slow in early infancy [28]. 
Accordingly, the trait is characterized as autosomal recessive: despite the ho-
motetrameric structure of the enzyme, the single allele coding for functional 
AHCY is obviously sufficient (in part, at least) for proper cell function. 
The incidence of AHCY deficiency is unknown, not only due to unaware-
ness of the disease but also because of limited availability of specific tests for 
SAH and SAM [38].
Figure 2. The structure of AHCY gene. Number present DNA base pairs. Coloured boxes 
present exons.
Contribution of in vitro studies: functional analyses of recombinant AHCY
Effects of the mutations found in AHCY deficient patients on the overall cat-
alytic and physico-chemical properties of the recombinant AHCY enzyme were 
extensively studied by Vugrek and co-workers. Characterization of recombinant 
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mutant AHCY revealed the correlation between the degree of inactivation of the 
enzyme and the severity of clinical manifestation. 
Consistent with findings that AHCY activity in WT/W112stop and WT/Y143 
heterozygotes (namely, the parents of the first patient) is slightly below normal 
and that activity in patients’ fibroblast extracts is only about 10% of control [28], 
the authors showed that purified recombinant Y143C AHCY retains only 34% 
activity as compared to recombinant wild-typ enzyme [39]. As expected, pro-
tein truncated by W112stop mutation showed no enzymatic activity. Therefore, 
it is not likely that the truncated molecule is in fact capable of forming hetero-
tetramers with full-length subunits, since tetramer assembly relies on the C-
terminal part of the protein which is completely absent in the truncation mu-
tant. Just as striking were the differences in basic physico-chemical properties 
of Y143C enzyme: the enzyme was shown to be extremely thermosensitive and 
prone to aggregation at slightly elevated temperatures, and the bound cofactor 
accumulated in its reduced (NADH) state. The latter observation suggests that 
Y143C mutation blocks the enzyme tetramer in its closed conformation. In this 
view, the catalytic step in which NADH is oxidized back to NAD+ is impaired. 
Similar NADH accumulation was observed in human [40] and rat [41] AHCY, 
also resulting in overall loss of activity. Three-dimensional structure seems to 
be altered and it will be interesting to examine the crystal structures when they 
will become available. 
The second genotype observed in a patient could be very informative from 
population genetics point of view, considering that the same mutation (Y143C) 
was found in a non-related patient in USA. Although the disease was not de-
tected at such early age as was the case with Croatian patients, his overall condi-
tion was much more serious. Indeed, the second mutation, A89V, was shown to 
significantly inactivate the enzyme (>70%), with pronounced effects on three-di-
mensional structure due to mutation-induced steric clash between amino acids 
at positions 89 and 84 (Val and Thr, respectively) [32]. The steric incopatibility 
hypothesis was confirmed by additional in vitro mutagenesis experiments. Since 
mutant A89V AHCY protein is able to form homo-tetramers in vitro, it is logical 
to assume that the formation of Y143C/A89V heterotetramers in patient’s cells 
can explain the decrease in activity of more than 80%, as measured in his eryth-
rocytes [31].
Effects of the last two mutations, found in a deceased infant (D86G and R49C) 
are clearly related to severity of such outcome. Both mutant proteins showed 
some unexpected properties in vitro [33]. D86G AHCY was almost impossible to 
express as soluble protein in E. coli, refolding has not been succesful, and specific 
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enzymatic activity could be boosted from initial 1.5% to approx. 15% only by 
inducing bacterial chaperones. As confirmed by targeted mutagenesis, the exis-
tence of negatively charged amino acid at position 86 is crucial for enzyme activ-
ity. On the other hand, R49C protein does not even form tetrameric complexes in 
absence of reducing agents. Authors detected significant NADH accumulation 
and probable formation of intramolecular disulfides due to newly introduced 
cysteine residue. Catalytic activity of recombinant R49C AHCY is decreased 
dramatically, showing only about 7% activity compared to wild-type enzyme. 
In this way, the results of in vitro studies of recombinant proteins clearly reflect 
the severity of symptoms described in corresponding patients. 
It is important to notice that all mutations found in AHCY-deficient patients 
tend to cluster into exons 2, 3 and 4. Although none of them affect residues that 
have been directly implicated in catalytic mechanism, it is obvious that they can 
significantly impair enzymatic capabilities as well as physico-chemical proper-
ties of the enzyme. Genotyping of larger number of individuals, combined with 
standardized SAH and SAM level tests could help estimate the real frequency 
of AHCY deficiency. 
Novel insights into the catalytic mechanism of AHCY
All four mutations found in AHCY deficient patients were studied in detail 
in our laboratory combining in vitro mutagenesis and in silico modeling tech-
niques [32, 33, 39]. Even though the amino acids directly involved in catalytic 
mechanism were mostly identified previously [42], we identified some novel pri-
mary structure restrictions. Consistent with the fact that it is highly improbable 
to find missense mutations in AHCY active site in a living organism (especially 
considering that the enzyme is a tetramer), mutations found in vivo have major 
impact on three-dimensional structure of AHCY, but they do not completely in-
activate the enzyme. Rather, they destabilize its structure by disturbing proper 
H-bond network or inducing sterical clashes leading to changed kinetic param-
eters. 
The AHCY subunit is composed of three domains with the peptide chain 
organized into 17 α-helices and 15 β-strands [43]. Y143C mutation is located at 
the end of α-helix 5, which is a part of catalytic domain. In wild-type AHCY a 
hydrogen bond between Y143 and E115 (α-helix 4) connects both helices, and 
this connection is abolished in mutated protein with cysteine in place of ty-
rosine at position 143. In vitro confirmation came from studies of recombinant 
AHCY where E115L mutation was induced into wild-type enzyme, mimicking 
the loss of this hydrogen bond as seen in Y143C protein. E115L enzyme showed 
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properties similar to Y143C AHCY. We proposed the inactivation mechanism in 
which the open-closed state transitions are impaired by Y143C mutation, block-
ing the tetramer in its closed state with SAH bound but impairing the efficiency 
of reduction step of the reaction. This is consistent with the decrease in specific 
enzymatic activity and the increase in Km for SAH, as well as with NADH ac-
cumulation [39]. A89V mutation inactivated the enzyme by more than 70%. We 
showed that the reason for this inactivation is the steric clash between Valine 89 
and Threonine 84. Although the difference in side-chain volume between ala-
nine and valine is minimal, the position 89 faces the cleft between two domains, 
which closes upon substrate binding. It was hypothesized that due to the steric 
clash the substrate or water molecule access/product release was impaired. Ad-
ditional mutagenesis experiments introducing several amino acids at positions 
89 and 84 confirmed this, also emphasizing the importance of polarity of amino 
acid at position 89 [32]. Regarding R49C and D86G mutations, somewhat less 
information could be obtained due to high instability of both mutant proteins. 
Nevertheless, the results indicate that the negative charge at position 86 is im-
portant for maintenance of enzyme activity [33]. 
All amino acids mutated in described studies were implicated in maintain-
ing AHCY activity and stability for the first time. X-ray diffraction experiments 
will surely reveal much more details; even though these results suggest that the 
present model of S-Adenosylhomocysteine hydrolysis may need refinement.
Therapeutic approach
All of the patients described above shared similar clinical features: severe 
myopathy and hypotonia, developmental delay and impaired myelination. At-
tention deficit/hyperactivity disorder was diagnosed in the first discovered 
patient; the patient with Y143C/A89V genotype also showed severe obsessive 
behavior. Apart from characteristic increse in SAM and especially SAH, all of 
the patients showed high aminotransferases and elevated creatine-kinase [29-
31]. The therapy included restricted methionine intake with supplementation 
of phosphatidylcholine, creatine and cysteine, which is a logical approach con-
sidering hypermethioninemia and possible inhibition of MTs, including PEMT. 
The results must be evaluated considering the patients’ age at the beginning of 
treatment. The oldest Croatian patient started with such therapy at the age of 
12.8 months, and showed some gradual improvement of alertness, communica-
tive skills, muscle strength and motor ability. Methionine, SAH and SAM levels 
decreased, ALT activities were lowered, brain myelination showed remarkable 
improvement, but CK levels remained high. Motor functions and expressive 
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speech were affected the most. Both the younger brothers of first patient have 
been enrolled in theraphy soon after birth, and some improvements were more 
pronounced (myelination, muscle pathology and liver status). Nevertheless, like 
the elder brother both remained hypotonic with high CK activities indicating 
that muscle pathology is not responsive to described therapy [38]. The patient 
with Y143/A89V genotype has been followed up as a case of isolated hyperme-
thioninemia until recently. Low methionine diet alone did not significantly im-
prove his condition, as expected, considering that he is AHCY deficient; possibly 
some irreversible damage occurred during long period without proper treat-
ment.
AHCY deficiency and cellular biochemistry
A great diversity of cellular processes is dependent on proper methylation 
status (or potential) of the cell, and transmethylation reactions have become an 
area of extensive research. Since enzymes responsible for those reactions gener-
ally deploy SAM as a methyl donor and are inhibited by SAH, AHCY deficiency 
can in fact be considered as the disorder of a cellular ‘methylation buffering sys-
tem’. The questions raised are: which methyltransferases are affected the most, 
how the degree of this inhibition connects to tissue-specific effects observed, 
what therapeutic approach would be the most efficient, and what fundamental 
knowledge can be extracted from those information?
There are probably much more than only 60 enzymes with methyltransferase 
activity in mammals: 0.6% - 1.6% of all human open reading frames (ORFs) are 
suspected to code for methyltransferases [44]. The extent of inhibition should 
vary between those enzymes depending on local concentration o SAH, and the 
effects should depend on cell/tissue specific role of the enzyme.
Clinical presentation directly points to some candidate methyltransferases. 
PEMT catalyses the synthesis of phosphatidylcholine (PTC), so the inhibition 
of this enzyme could cause the PTC decrease detected in patients, which is in 
turn connected with liver and muscle function. Myelin basic protein-arginine 
N-methyltransferase is about 90% inhibited by 100x elevation of SAH [45], and 
myelination insufficiency might be the result of such inhibition. On the other 
hand, the pathology of the disease is, at least in part, connected to changes in 
DNA methylation. Repeated measurements by [3H]dCTP incorporation showed 
hypermethylation of patients DNA, which is opposite of what is expected con-
sidering the inhibitory effect of SAH on methyltransferases. The reasons for this 
phenomenon are still to be elucidated, although it can be speculated that spe-
cific DNA MTs are not so sensitive to increased SAH concentrations, and exert 
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their function properly. Elevated cellular SAM and the fact that some other MTs 
stay inhibited, therefore leaving excess SAM for DNMTs could explain hyper-
methylation of patient’s DNA. In a exhaustive review by Clarke and Banfield 
many MTs are listed with their respective sensitivity to SAH [46]: at SAM/SAH 
ratio of 0.3, DNMT1 retains 23% activity, while PEMT activity is lowered to only 
6%. So it can be assumed that strong inhibition of PEMT is the reason for low 
phosphatydilcholine levels, while the same intracellular SAM/SAH ratios do not 
have such dramatic effect on DNMTs. This comparison is just an example to 
show that not all methylations in a cell would be affected to the same extent; fur-
ther research is necessary at the global genomic/proteomic level. Interestingly, 
among the enzymes listed in review mentioned, one of the most SAH-sensitive 
MTs is protein-L-isoaspartyl-methyltransferase (PIMT). This is the key enzyme 
involved in repair of ‘isoaspartyl lesions’, namely, isoaspartate residues formed 
by isomerization of aspartates. Such residues are a measure of non-enzymatic 
damage that occurs during molecular aging of proteins, so it would be interest-
ing to evaluate this repair mechanism under conditions of low SAM/SAH ratio 
found in AHCY- deficient patients. 
Many of potential disturbances might be cell- or tissue specific, due to dif-
ferential expression and roles of different enzymes and other macro- and small 
molecules in various cell types and tissues. On the other hand, some of them are 
probably more general, like adenosine and glutathione depletion. 
The central position of AHCY in methionine pathway and methylation pro-
cesses indicates that AHCY deficiency affects a wide array of reactions and pat-
hways, thus having the potential to serve as an invaluable model system for both 
in vitro and in vivo studies.  
AHCY deficiency research – Perspectives and concluding remarks
Methylation of various cellular compounds including DNA, RNA, protein, 
lipid as well as function of many cellular processes including epigenetic, protein 
processing, signaling and lipid biosynthesis are affected by AHCY deficiency. 
Besides that, methylation is important for protein-protein interactions, viral re-
plication, histone modifications, transcription, chromatin structure, X chromo-
some inactivation, genomic imprinting and chromosome stability. On the other 
hand, aberrant methylation is a widespread phenomenon in cancer and may be 
among the earliest changes during oncogenesis. 
Study of AHCY deficiency might provide fundamental insights into pro-
cesses of DNA methylation and other epigenetic modifications. Also, AHCY 
deficiency is an excellent natural model to study wide range of inherited and 
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acquired human pathological conditions, in which disturbed methylation is part 
of the pathogenesis. Thus, activities focusing on methylation and the human 
methylome should have broad impact.
Figure 3 outlines several avenues for methylome research by using AHCY 
deficiency as model system. In particular, new insights in the human methylo-
me are envisaged by researching methylation status of: 
• Promoter regions of genomic DNA (and other regions, i.e. exons, introns, 
LTRs, etc)
• miRNA promoters (one of the hottest topics in research at present moment)
• mRNA (5’-capping of mRNA etc.)
• a plethora of proteins (Histone lysine and arginine methylation etc.)
• Other molecules and processes mentioned above
Figure 3: Cartoon showing backbone of research platform AHCYdomics
In summary, using new technology based on ‘omics’ approaches in combi-
nation with AHCY deficiency model system – thereby creating the research plat-
form AHCYdomics, should open up several avenues for methylome research. In 
particular, research on DNA and histone methylation and other still enigmatic 
processes controlling gene expression and human development may be tackled 
using AHCYdomics as research platform. 
89
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Sažetak
Nedostatna aktivnost S-adenozilhomocistein hidrolaze (AHCY): prirodni modelni sustav za 
istraživanje staničnih metilacija
Nedostatna aktivnost AHCY-ja naziv je novog poremećaja metilacijskih procesa kod čo-
vjeka, otkrivenog u Hrvatskoj, koji je prirodni model u istraživanju metiloma. Metilacijski pro-
cesi važni su u regulaciji staničnih procesa te imaju ključnu ulogu u regulaciji ekspresije gena, 
genskog upisa (imprinting), prijenosa signala, sintezi proteina te metabolizmu lipida. Upravo 
zbog tako širokog spektra funkcija, proučavanje metilacije zahtijeva interdisciplinarni pristup 
istraživanju. Povezivanje genomike, proteomike, celomike, lipidomike i metabolomike te ostalih 
‘omics’ pristupa dovest će do novog integriranog područja istraživanja – ‘AHCYdomika’ – te 
stvaranja nove platforme za istraživanje metilacijskih procesa temeljene na nedostatnoj aktivno-
sti AHCY-ja. Takva istraživačka platforma omogućit će potpuno iskorištavanje mogućnosti koje 
pruža model baziran na ovom poremećaju, doprinijeti razvoju novih metoda te, nakraju, boljem 
razumijevanju ljudskog metiloma.
Ključne riječi: methylation disorder; metabolic disease; genotype-phenotype; homocysteine; 
human mutation; S-Adenosylmethionine (SAM); S-Adenosylmethionine (SAM); S-Adenosylho-
mocysteine-hydrolase (AHCY)
